Angiotensin II antagonists: a new class of antihypertensive agent

Détails

ID Serval
serval:BIB_46740D363DC8
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Angiotensin II antagonists: a new class of antihypertensive agent
Périodique
British Journal of Clinical Practice
Auteur(s)
Waeber B., Brunner  H. R.
ISSN
0007-0947
Statut éditorial
Publié
Date de publication
1996
Peer-reviewed
Oui
Volume
50
Numéro
5
Pages
265-8
Langue
anglais
Notes
Journal Article
Review
Résumé
Losartan is an orally active angiotensin II antangonist that selectively blocks effects mediated by the stimulation of the AT1 subtype of the angiotensin II receptor. This agent, at doses of 50-150mg/day, is as effective at lowering blood pressure as chronic angiotensin converting enzyme (ACE) inhibitors. Losartan is generally well tolerated and has an incidence of adverse effects very similar, in double-blind controlled trials, to that of placebo. It does not cause coughing, the most common side-effect of the ACE inhibitors, most probably because angiotensin II antagonism has no impact on ACE, an enzyme known to process bradykinin and other cough-inducing peptides. Losartan is a promising antihypertensive agent with the potential to become a first-line option for the treatment of patients with high blood pressure.
Mots-clé
Antihypertensive Agents/pharmacokinetics/*pharmacologyBiphenyl Compounds/pharmacokinetics/*pharmacologyHumansImidazoles/pharmacokinetics/*pharmacologyLosartanReceptors, Angiotensin/*antagonists & inhibitorsTetrazoles/pharmacokinetics/*pharmacology
Pubmed
Web of science
Création de la notice
06/03/2009 13:00
Dernière modification de la notice
03/03/2018 16:47
Données d'usage